The Council for Responsible Nutrition on Thursday issued a statement regarding the growing controversy surrounding Lazy Cakes — a brownie containing melatonin, an ingredient that helps establish more normal sleeping patterns — that has been cited in a New York Times article as having “flagrantly mimic[ked] the soothing effects of hash brownies.”
According to a report in the May issue of Cell Metabolism, while drugs known as thiazolidinediones, or TZDs, are widely used in diabetes treatment, they have effects on the kidneys that lead to fluid retention as the volume of plasma in the bloodstream expands.
Patients with HIV who immediately started antiretroviral therapy significantly reduced the risk of spreading the virus to an uninfected partner, compared with those who delayed therapy, according to results of a multinational study. The study also found that antiretroviral therapy reduced the risk of transmission by 96%.
Cobalis on Tuesday began airing 60-second television commercials in support of its PreHistin allergy defense formula across national cable and satellite networks as part of a planned $5 million spend, the company announced.
Patients with moderate to severe rheumatoid arthritis who respond to 12 weeks of treatment with a drug made by UCB are more likely to show improvement in their condition in the long run, according to results of a study published in the Journal of Rheumatology.
Julep, a boutique salon concept that offers manicure and pedicure parties, is looking to help beauty mavens enjoy pedicure parties at home with the launch of its new Julep At-Home Mani Pedi Party Set for Six.
The Food and Drug Administration is moving forward in the creation of a regulatory approval pathway for follow-on biologics and is requesting input from stakeholders and the public, the agency said Monday.
Drug maker Merck announced that it has kicked off an initiative that includes a wide range of public education and patient support programs, as well as research efforts to help improve care for people living with chronic hepatitis C virus infections.
Napo Pharmaceuticals has filed a lawsuit against Salix Pharmaceuticals, alleging that the latter breached commitments under an agreement to develop and commercialize a proprietary gastrointestinal compound.